5-year disease-free survival and overall survival were 64.7% and 66, 3% respectively. The highest in patients at stage IIIA (70.2% and 76%), then in patients at stage IIIB (67, 8% and 63.5%) and the lowest in patients at stage IIIC (26.3% and 31%).